BET Inhibitors Active in DLBCL and Other Lymphomas, Two Early Trials Show

BET inhibitors CPI-1205 and CPI-0610 have shown promise in two phase I trials in DLBCL and other lymphomas, investigators at TAT 2018 reported.

Source: CancerNetwork - March 29, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Diffuse Large B-Cell Lymphoma Hematologic Malignancies News Source Type: news